Hyderabad based NATCO Pharma Limited (NSE:NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR 918.9 Crore for the first quarter ended on 30th June 2022, as against INR 427.3 Crore for the same period last year, reflecting a growth of 115%. The net profit for the period, on a consolidated basis, was INR 320.4 Crores as against INR 75.0 Crores same period last year.

During the quarter, export sales of Lenalidomide product to United States was a major contributor to the revenue and profitability of the business. Pharma domestic formulations business remained steady. On the expense side, there was a one-time cost associated with retirement schemes during the quarter and higher than usual R&D costs for product development.

(C) 2022 Electronic News Publishing, source ENP Newswire